Kaken Pharmaceutical: [Summary] Consolidated performance for the first quarter of the fiscal year 2024 (3 months until June 30, 2024) [JGAAP]
Kaken Pharmaceutical: Report on the transfer of shares in relation to third-party allotment (treasury stock).
Kaken Pharmaceutical: Independent Officer Notification Form
Kaken Pharmaceutical: Transfer of intellectual property of “NM26” and conclusion of a sales partnership option agreement
Kaken Pharmaceutical: [Delay] Announcement of measures to realize management that is conscious of capital costs and stock prices
Kaken Pharmaceutical: Construction of a manufacturing plant for fermented pesticide raw materials at the Shizuoka Plant
Kaken Pharmaceutical: Measures aimed at realizing management that is conscious of capital costs and stock prices
Kaken Pharmaceutical: [Overview] Consolidated financial results for the fiscal year ended 2024/3/31 [JGAAP]
Kaken Pharmaceutical: Succession of manufacturing and sales approval for 2 products from Eisai
Kaken Pharmaceutical: [Delayed][Summary]Consolidated Financial Results for the Third Quarter of Fiscal 2023 (Nine-Month Period Ended December 31, 2023) [JGAAP]
Kaken Pharmaceutical: Share transfer report relating to third-party allotment (treasury stock)
Kaken Pharmaceutical: [Delayed][Summary]Consolidated Financial Results for the Second Quarter of Fiscal 2023 (Six-Month Period Ended September 30, 2023) [JGAAP]
Kaken Pharmaceutical: Submission of a sales approval application for the treatment of primary axillary hyperhidrosis “ECLOC” in South Korea
Kaken Pharmaceutical: Share transfer report relating to third-party allotment (treasury stock)
Kaken Pharmaceutical: Share transfer report relating to third-party allotment (treasury stock)
Kaken Pharmaceutical: Share transfer report relating to third-party allotment (treasury stock)
Kaken Pharmaceutical: Share transfer report relating to third-party allotment (treasury stock)
Kaken Pharmaceutical: Share transfer report relating to third-party allotment (treasury stock)
Kaken Pharmaceutical: [Delayed][Summary]Consolidated Financial Results for the First Quarter of Fiscal 2023
Kaken Pharmaceutical: Share transfer report relating to third-party allotment (treasury stock)
No Data
No Data